Lisa A. Carey, MD, FASCO, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, speaks on the clinical implications and therapeutic opportunities arising from the latest research in tumor targets, DNA response, and immunotherapy in triple negative breast cancer (TNBC). Dr Carey discusses the development of a clinical framework for the heterogeneity in tumor phenotypes and in the emerging understanding of the immune microenvironment and how this will affect personal challenges for patients living with TNBC. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
